An LC-MS based study of the metabolic profile of primaquine, an 8-aminoquinoline antiparasitic drug, with an in vitro primary human hepatocyte culture model

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 39, Issue 2, 2014, Pages 139-146

  Jin, X ^a   Pybus, B S ^a   Marcsisin, S R ^a   Logan, T ^a   Luong, T L ^a   Sousa, J ^a   Matlock, N ^a   Collazo, V ^a   Asher, C ^a   Carroll, D ^a   Olmeda, R ^a   Walker, L A ^b   Kozar, M P ^a   Melendez, V ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

Metabolism; Pharmacogenomics; Transport

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DIMETHYLANILINE MONOOXYGENASE; FLUVOXAMINE; KETOCONAZOLE; OMEPRAZOLE; PRIMAQUINE; QUINIDINE; SULFAPHENAZOLE;

ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG METABOLISM; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; ION TRAP MASS SPECTROMETRY; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; LIVER CELL CULTURE; MALARIA; MASS SPECTROMETRY; QUALITY CONTROL;

ANTIMALARIALS; CELLS, CULTURED; CHROMATOGRAPHY, LIQUID; HEPATOCYTES; HUMANS; PRIMAQUINE; TANDEM MASS SPECTROMETRY;

EID: 84892772506     PISSN: 03787966     EISSN: 21070180     Source Type: Journal    
DOI: 10.1007/s13318-013-0139-8     Document Type: Article

References (19)

1. Baker JK, Yarber RH, Nanayakkara NPD, McChesney JD, Homo F, Landau I (1990) Effect of aliphatic side-chain substituents on the antimalarial activity and on the metabolism of primaquine studied using mitochondria and microsome preparations. Pharm Res 7:91-95 (Pubitemid 20115806)
2. Bowman ZS, Morrow JD, Jollow DJ, McMillan DC (2005) Primaquine-induced hemolytic anemia: role of membrane lipid peroxidation and cytoskeletal protein alterations in the hemotoxicity of 5-hydroxyprimaquine. J Pharmacol Exp Ther 314(2):838-845 (Pubitemid 41043869)
3. Cashman JR (1995) Structural and catalytic properties of the mammalian flavin-containing monooxygenase. Chem Res Toxicol 8:165-181
4. Clark AM, Hufford CD, Mcchesney BP(1990) Primaquine: metabolism by microorganisms and 13C nuclear magnetic resonance assignments. Antimicrob Agent Chemother 19(2):337-341
5. Constantino L, Paixao P, Moreira R, Portela MJ, Do Rosario VE, Iley J (1999) Metabolism of primaquine by liver homogenate fractions: evidence for monoamine oxidase and cytochrome P450 involvement in the oxidative deamination of primaquine to carboxyprimaquine. Exp Toxicol Pathol 51:299-303 (Pubitemid 29334356)
6. Gomez-Lechon MJ, Donato MT, Castell JV, Jover R (2003) Human hepatocytes as a tool for studying toxicity and drug metabolism. Curr Drug Metab 4:292-312 (Pubitemid 36958330)
7. Jacobson AR, Coffin SH, Shearson CM, Sayre LM (1987) S, S' Iminodipropionitrile (IDPN) neurotoxicity: a mechanistic hypothesis for toxic activation. Mol Toxicol 1:17-34
8. Lecluyse E, Madan A, Hamilton G, Carroll K, Dehaan R, Parkinson A (2000) Expression and regulation of cytochrome P450s in primary cultures of human hepatocytes. J Biochem Mol Toxicol 14:177-188
9. Maurice M, Pichard L, Daujat M, Fabre I, Joyeux H, Domergue J, Maurel P (1992) Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB J 6:752-758
10. Murphy DL, Donnelly CH, Richelson E, Fuller RW (1978) N-Substituted cyclopropylamines as inhibitors of MAO-A and -B forms. Biochem Pharmacol 27:1767-1769 (Pubitemid 9009638)
11. Na-Bangchang K, Congpuong K (2007) Current malaria status and distribution of drug resistance in east and southeast Asia with special focus to Thailand. Tohoku J Exp Med 211:99-113
12. Nace CG, Genter MB, Sayre LM, Crofton KM (1997) Effect of methimazole, an FMO substrate and competitive inhibitor, on the neurotoxicity of 3,3′-iminodipropionitrile in male rats. Fundam Appl Toxicol 37:131-140
13. Naritomi Y, Terashita S, Kimura S, Suzuki A, Kagayama A, Sugiyama Y (2001) Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab Dispos 29(10):1316-1324 (Pubitemid 32896581)
14. Oxenkrug GF, Balon R, McCauley RB, Mclntyre IM (1989) Effects of tranylcypromine on serotonin content and monoamine oxidase activity of the human blood platelet. Human Psychopharmacol Clin Exp 5(2):155-157 (Pubitemid 20196281)
15. Runge D, Kohler C, Kostrubsky VE, Jager D, Lchmann T, Runge DM, May U, Stolz DB, Strom SC, Fleig WE, Michalopoulos GK (2000) Induction of cytochrome P450 (CYP) 1A1, CYP1A2, and CYP3A4 but not of CYP2C9, CYP2C19, multidrug resistance (MDR-1) and multidrug resistance associated protein (MRP-1) by prototypial inducers in human hepatocytes. Biochem Biophys Res Commun 273:333-341 (Pubitemid 30426907)
16. StoÉrmer E, Roots I, Brockmoller J (2000) Bebzydamine N-oxidation as an index reaction reflecting FMO activity in human liver microsomes and impact of FMO3 polymorphisms on enzyme activity. Br J Clin Pharmacol 50:553-561
17. Vale N, Moreira R, Gomes P (2009) Primaquine revisited six decades after its discovery. Eur J Med Chem 44(3):937-953
18. Wilkinson GR (1987) Clearance approaches in pharmacology. Pharmacol Rev 39:1-47
19. Yoichi N, Shigeyuki S, Sumihisa K, Akira S, Akira K, Yuichi S (2001) Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab Dispos 29(10):1316-1324